Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton Sells 5,479 Shares

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 5,479 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $9.79, for a total value of $53,639.41. Following the completion of the sale, the chief financial officer now directly owns 131,963 shares in the company, valued at approximately $1,291,917.77. The trade was a 3.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Mark Leonard Singleton also recently made the following trade(s):

• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The shares were sold at an average price of $10.19, for a total value of $66,214.62.

Bioventus Trading Down 3.3 %

BVS opened at $9.12 on Thursday. The business has a fifty day moving average price of $10.11 and a 200 day moving average price of $11.00. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 12 month low of $3.90 and a 12 month high of $14.38. The stock has a market capitalization of $747.33 million, a price-to-earnings ratio of -14.95 and a beta of 0.86.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and raised their target price for the company from $12.00 to $13.00 in a report on Tuesday, December 17th. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research note on Monday, March 17th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. acquired a new stake in shares of Bioventus in the 3rd quarter valued at $210,000. Quest Partners LLC purchased a new stake in Bioventus during the 3rd quarter worth about $51,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Bioventus during the 3rd quarter worth about $3,092,000. Intech Investment Management LLC purchased a new position in shares of Bioventus in the 3rd quarter valued at about $167,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Bioventus by 38.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock worth $4,662,000 after acquiring an additional 109,359 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.